AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS - 2023 Issue 4; New/Revised ICD-10-PCS Codes Section X – New Technology
Introduction of New Therapeutic Substances
Nine new substance values were added to table XW0, Introduction, Anatomical Regions, for the substances listed below. Please note that all of the substances have a qualifier value of 9 New Technology Group 9.Device/Substance/Technology J Quizartinib Antineoplastic K Sulbactam-Durlobactam L Elranatamab Antineoplastic N SER-109 P Glofitamab Antineoplastic Q Posoleucel R Rezafungin S Epcoritamab Monocolonal Antibody T Mephalan Hydrochloride Antineoplastic QuizartinibQuizartinib is used to treat adult patients with newly diagnosed acute myeloid leukemia (AML) that is FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) positive. This drug is a small molecule novel tyrosine kinase inhibitor expressly developed as a...
Subscribe or sign in to view the full article.
Article Overview
This article reviews newly added therapeutic substances and the coding updates associated with their administration. It is useful for hospital coders, CDI staff, and reimbursement teams who work with ICD-10-PCS procedure coding for newer drugs, biologics, and transplant-related therapies. The discussion covers the affected table, the general clinical uses of each substance, and where administration-related code updates were created.
Why This Topic Matters
New substance additions can affect inpatient procedure reporting, coding workflow, and consistency in documenting administration of recently introduced therapies. Understanding these updates helps coding teams recognize when new ICD-10-PCS content applies to medication and biologic administration scenarios.
Article Sections
-
New substance values added to table XW0
Overview of the additions to the ICD-10-PCS table and the shared qualifier noted for the new entries.
-
Quizartinib
General clinical context for a new antineoplastic therapy and its use in leukemia care.
-
Sulbactam-Durlobactam
Background on a new antibacterial combination therapy and the administration coding updates associated with it.
-
Elranatamab
General overview of a new bispecific antibody used in multiple myeloma treatment.
-
SER-109
Discussion of a microbiome-based therapy and its role in recurrent infection management.
-
Glofitamab
General information on a new lymphoma therapy and the associated administration coding updates.
-
Posoleucel
Overview of a virus-specific cell therapy used in transplant-related care settings.
-
Rezafungin
Background on a new antifungal therapy and the administration coding updates associated with it.
-
Epcoritamab Monoclonal Antibody
General overview of a new bispecific monoclonal antibody used for relapsed or refractory lymphoma.
-
Melphalan Hydrochloride Antineoplastic
Discussion of a hepatic-directed antineoplastic therapy and related procedure coding considerations.
What You Will Learn
- Which newly added therapeutic substances are discussed in the article.
- How the article frames the clinical purpose of each new substance.
- Which therapies have related ICD-10-PCS administration updates.
- Which broad treatment areas are affected by the new additions.
Who Should Read This
- Hospital inpatient coders
- Clinical documentation integrity specialists
- Health information management professionals
- Reimbursement and revenue cycle teams
- Coding educators and auditors
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com